Evaluation of Type 1 Error Rates in Duplex Sequencing for Mutagenicity Testing Using Vehicle Control Data and Simulation Analyses
Environmental and Molecular Mutagenesis · 2026
DOI: 10.1002/em.70067 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environmental and Molecular Mutagenesis, 2026. Verfasst von Andrew Williams und 6 weiteren Autor:innen. Beteiligte Einrichtung: Environmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Sequence Analysis, DNA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canada Research Chairs, Burroughs Wellcome Fund.
Abstract (Originalsprache)
Accurate mutation detection and quantification are crucial for understanding mutagenesis and its potential health implications. Traditional in vivo mutagenicity assays, such as the transgenic rodent gene mutation assay, are limited by their focus on single reporter genes and inability to efficiently generate mutation spectra. Error‐corrected sequencing (ECS) technologies like Duplex Sequencing (DS) offer significant advantages, including extremely low error rates and the ability to measure mutation frequencies (MFs) across various tissues and model organisms. Before ECS approaches can be adopted for regulatory purposes, their performance characteristics, particularly the type 1 error rate, must be rigorously established. We evaluated the type 1 error rate of DS through empirical analysis of vehicle control data and complementary simulation studies. Using 138 control mouse liver samples from 28 studies analyzed with the TwinStrand Mouse Mutagenesis Panel, we performed variance component analysis and found that experiment‐level variability exceeds within‐experiment sample variability. To evaluate the impact of between‐study heterogeneity, we simulated overdispersed binomial data informed by the observed variance components. Removing the most variable studies reduced overdispersion and improved control of the type 1 error rate. Our findings demonstrate that DS maintains appropriate type 1 error rates (~0.05) when study heterogeneity is limited and at least four samples per group are used. Under greater overdispersion, sample sizes of five or six per group may be needed to achieve comparable control of the type 1 error rate. These results underscore the importance of combining empirical and simulation‐based approaches to evaluate and optimize the statistical performance of emerging genomic technologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Environmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario, Canada.
- Pfizer Worldwide Research, Development, and Medical, Groton, Connecticut, USA.
- Nonclinical Safety, Bristol Myers Squibb, New Brunswick, New Jersey, USA.
- Department of Biology, University of Ottawa, Ottawa, Ontario, Canada.
ORCID-Profile: Andrew Williams, Shaofei Zhang
Förderung
- Canada Research Chairs
- Burroughs Wellcome Fund
Zitieren
APA
Williams, A., Zhang, S., Li, D., Sun, W., Schuler, M. J., Marchetti, F., & Yauk, C. L. (2026). Evaluation of Type 1 Error Rates in Duplex Sequencing for Mutagenicity Testing Using Vehicle Control Data and Simulation Analyses. Environmental and Molecular Mutagenesis. https://doi.org/10.1002/em.70067
Vancouver
Williams A, Zhang S, Li D, Sun W, Schuler MJ, Marchetti F, et al. Evaluation of Type 1 Error Rates in Duplex Sequencing for Mutagenicity Testing Using Vehicle Control Data and Simulation Analyses. Environmental and Molecular Mutagenesis. 2026. doi:10.1002/em.70067
BibTeX
@article{Williams2026,
author = {Williams, Andrew and Zhang, Shaofei and Li, Dingzhou and Sun, Wen and Schuler, Maik J and Marchetti, Francesco and Yauk, Carole L},
title = {Evaluation of Type 1 Error Rates in Duplex Sequencing for Mutagenicity Testing Using Vehicle Control Data and Simulation Analyses},
journal = {Environmental and Molecular Mutagenesis},
year = {2026},
doi = {10.1002/em.70067}
}
EUVIMED